Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer

33Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

PURPOSEAdjuvant radiotherapy (RT) is used for women with early-stage invasive breast cancer treated with breast-conserving surgery. However, some women with low risk of recurrence may safely be spared RT. This study aimed to identify these women using a molecular-based approach.METHODSWe analyzed two randomized trials of women with node-negative invasive breast cancer to ± RT following breast-conserving surgery: SweBCG91-RT (stage I-II, no adjuvant systemic therapy) and Princess Margaret (age 50 years or older, T1-T2, adjuvant tamoxifen). Transcriptome-wide profiling was performed (Affymetrix Human Exon 1.0 ST microarray). Patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative tumors and with gene expression data were included. The SweBCG91-RT cohort was divided into training (N = 243) and validation (N = 354) cohorts. A 16-gene signature named Profile for the Omission of Local Adjuvant Radiation (POLAR) was trained to predict locoregional recurrence (LRR) using elastic net regression. POLAR was then validated in the SweBCG91-RT validation cohort and the Princess Margaret cohort (N = 132).RESULTSPatients categorized as POLAR low-risk without RT had a 10-year LRR of 6% (95% CI, 2 to 16) and 7% (0 to 27) in SweBCG91-RT and Princess Margaret cohorts, respectively. There was no significant benefit from RT in POLAR low-risk patients (hazard ratio [HR], 1.1 [0.39 to 3.4], P =.81, and HR, 1.5 [0.14 to 16], P =.74, respectively). Patients categorized as POLAR high-risk had a significant decreased risk of LRR with RT (HR, 0.43 [0.24 to 0.78], P =.0055, and HR, 0.25 [0.07 to 0.92], P =.038, respectively). An exploratory analysis testing for interaction between RT and POLAR in the combined validation cohort was performed (P =.066).CONCLUSIONThe novel POLAR genomic signature on the basis of LRR biology may identify patients with a low risk of LRR despite not receiving RT, and thus may be candidates for RT omission.

Cite

CITATION STYLE

APA

Sjöström, M., Fyles, A., Liu, F. F., McCready, D., Shi, W., Rey-Mcintyre, K., … Karlsson, P. (2023). Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer. Journal of Clinical Oncology, 41(8), 1533–1540. https://doi.org/10.1200/JCO.22.00655

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free